Skip to main content
  • Home
  •  Hypertrophic Cardiomyopathy in Review: Highlights of 2022

Hypertrophic Cardiomyopathy in Review: Highlights of 2022

Topic:
  • Structural Heart Disease

Available Credit:

  • 0.25 AMA PRA Credit

Course Published On:

Course Expiry Date:

HCM in Review: Highlights of 2022
No ratings

Release / Expiration Date

6 January 2023 – 6 January 2024

Method of Participation

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. There is no fee to participate in the activity or for the generation of the certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Radcliffe Medical Education. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

Support Statement

This activity is supported by an educational grant from Bristol Myers Squibb.

Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

 

The following financial relationships have been provided by Milind Desai, MD:

Grants/Research Support: Pfizer, Ionis, Ultomics

Consultant: Bristol Myers Squibb, Eidos

Honoraria: Alnylam, Eidos, Pfizer

 

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: The use of unlabelled drugs (aficamten and mavacamten) will be discussed.

Staff and Reviewer Disclosures

ACHL and Radcliffe Medical Education staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Terms & Conditions

The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

 

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

 

This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Other Allied Healthcare Professionals

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments

Speaker

Milind Y Desai

Cleveland Clinic

Dr Desai works in the Cardiovascular Medicine and Heart and Vascular Institute at the Cleveland Clinic. 

View full profile
0.25 AMA PRA Credit

Related Courses

TAVI – Is Lifetime Patient Management the Alpha to Omega of Contemporary Practice?
  • 1.00 EBAC

Learning objectives

  • Evaluate the factors influencing coronary access in different valve designs
  • Formulate strategies to optimise coronary access based on valve characteristics
  • Evaluate the role of valve design in reducing pacemaker implantation rates and enhancing future coronary access
  • Learn the step-by-step process for achieving optimum implant depth during TAVI
  • Apply guidelines and best practices for achieving and confirming optimum implant depth in TAVI procedures
See more
Getting it Right First Time in Severe Aortic Stenosis - Key Insights for Long Term Success
  • 1.00 EBAC

Learning objectives

  • Recall current and predicted trends in TAVI with respect to preserving coronary access
  • Consider determining factors for choosing valves in low risk populations
  • Discuss solutions for maximising valve durability and haemodynamics and for treating degenerated TAVI
See more
TIO 2023 – Key Issues in TAVI - Live Cases and Discussions
  • 1.00 EBAC

Learning objectives

  • Compare the utility of repair and replacement valve technology in mitral regurgitation
  • Individualise valve choice for aortic regurgitation based on valve durability and patient features
  • Recall the utility and limitations of specialty balloons
  • Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
  • Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
  • Identify suitable patients for interatrial shunting
  • Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
See more
TIO 2023 – Key Issues in TAVI
  • 1.00 EBAC

Learning objectives

  • Compare the utility of repair and replacement valve technology in mitral regurgitation
  • Individualise valve choice for aortic regurgitation based on valve durability and patient features
  • Recall the utility and limitations of specialty balloons
  • Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
  • Identify suitable patients for interatrial shunting
  • Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
See more
TIO 2023 – Symposium: Lifetime Patient Management Greater Expectations: Is TAVI Rising to The Challenge?
  • 1.00 EBAC

Learning objectives

  • Recall the latest data on durability and clinical outcomes for TAVI
  • Understand how TAVI is advancing and become aware of future treatment options for lifetime management of patients with aortic valve disease
  • Become more confident using TAVI in cases with complex anatomy
See more
TIO 2023 – Atrioventricular Valve Replacement Beyond TEER? – Live Cases & Discussions
  • 1.00 EBAC

Learning objectives

  • Compare the utility of repair and replacement valve technology in mitral regurgitation
  • Individualise valve choice for aortic regurgitation based on valve durability and patient features
  • Recall the utility and limitations of specialty balloons
  • Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
  • Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
  • Identify suitable patients for interatrial shunting
  • Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
See more
TIO 2023 – Atrioventricular Valve Replacement Beyond TEER?
  • 1.00 EBAC

Learning objectives

  • Compare the utility of repair and replacement valve technology in mitral regurgitation
  • Individualise valve choice for aortic regurgitation based on valve durability and patient features
  • Recall the utility and limitations of specialty balloons
  • Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
  • Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
  • Identify suitable patients for interatrial shunting
  • Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
See more